Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner

Open access
Huang, Jiapeng, Sun, Wei, Wang, Zhihong, Lv, Chengzhou, Zhang, Ting, Zhang, Dalin, Dong, Wenwu, Shao, Liang, He, Liang, Ji, Xiaoyu, Zhang, Ping, Zhang, Hao · 2022 · Journal of Experimental & Clinical Cancer Research

Abstract

Background: N6-methyladenosine (m 6 A) modification is the most common chemical modification in mammalian mRNAs, and it plays important roles by regulating several cellular processes. Previous studies report that m 6 A is implicated in modulating tumorigenesis and progression. However, dysregulation of m 6 A modification and effect of m 6 A demethylase fat-mass and obesity-associated protein (FTO) on glucose metabolism has not been fully elucidated in papillary thyroid cancer (PTC). Methods: Quantitative real-time PCR (qRT-PCR), western blotting and immunohistochemistry were performed to explore the expression profile of FTO in PTC tissues and adjacent non-cancerous thyroid tissues. Effects of FTO on PTC glycolysis and growth were investigated through in vitro and in vivo experiments. Mechanism of FTO-mediated m 6 A modification was explored through transcriptome-sequencing (RNA-seq), methylated RNA immunoprecipitation sequencing (MeRIP-seq), MeRIP-qPCR, luciferase reporter assays, RNA stability assay and RNA immunoprecipitation assay. Results: FTO expression was significantly downregulated in PTC tissues. Functional analysis showed that FTO inhibited PTC glycolysis and growth. Further analyses were conducted to explore FTO-mediated m 6 A modification profile in PTC cells and Apolipoprotein E (APOE) was identified as the target gene for FTO-mediated m 6 A modification using RNA-seq and MeRIP-seq. FTO knockdown significantly increased APOE mRNA m 6 A modification and upregulated its expression. FTO-mediated m 6 A modification of APOE mRNA was recognized and stabilized by the m 6 A reader IGF2BP2. The findings showed that APOE also promoted tumor growth through glycolysis in PTC. Analysis showed that FTO/APOE axis inhibits PTC glycolysis by modulating IL-6/JAK2/STAT3 signaling pathway. Conclusion: FTO acts as a tumor suppressor to inhibit tumor glycolysis in PTC. The findings of the current study showed that FTO inhibited expression of APOE through IGF2BP2-mediated m 6 A modification and may inhibit glycolytic metabolism in PTC by modulating IL-6/JAK2/STAT3 signaling pathway, thus abrogating tumor growth.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13046-022-02254-z

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 FTO is downregulated and the total m6A level was increased in PTC. a-b Expression level of m6A modification enzymes in TCGA and GEO database (GSE60542, GSE27155 and GSE3467). c Relative expression levels of m6A modification enzymes in 30 pairs PTC tissues and paired non-cancerous tissues as determined by qRT-PCR. d Total m6A levels in 5 pairs PTC samples as determined by m6A RNA Methylation Quantification Kit. e Relative expression levels of FTO in 100 pairs of PTC tissues and adjacent non-cancerous tissues as determined by qRT-PCR. f Representative photographs of IHC staining for FTO protein expression in PTC tissues and adjacent non-cancerous tissues (Cohort 2). Scale bars: 50 μm (400X). g Representative photographs of western blotting for FTO protein expression in PTC tissues (T) and paired non-cancerous tissues (N) (Cohort 3). *P < 0.05, **P < 0.01
Fig. 1 FTO is downregulated and the total m6A level was increased in PTC. a-b Expression level of m6A modification enzymes in TCGA and GEO database (GSE60542, GSE27155 and GSE3467). c Relative expression levels of m6A modification enzymes in 30 pairs PTC tissues and paired non-cancerous tissues as determined by qRT-PCR. d Total m6A levels in 5 pairs PTC samples as determined by m6A RNA Methylation Quantification Kit. e Relative expression levels of FTO in 100 pairs of PTC tissues and adjacent non-cancerous tissues as determined by qRT-PCR. f Representative photographs of IHC staining for FTO protein expression in PTC tissues and adjacent non-cancerous tissues (Cohort 2). Scale bars: 50 μm (400X). g Representative photographs of western blotting for FTO protein expression in PTC tissues (T) and paired non-cancerous tissues (N) (Cohort 3). *P < 0.05, **P < 0.01CC BY · PubMed Central
Fig. 2 FTO inhibits PTC cell proliferation in vitro and in vivo. a Relative protein expression of FTO in the normal thyroid follicular epithelial cells and PTC cells as determined by western blotting. b Knockdown efficiency of si-FTO-1/2 in K1 cells as determined by qRT-PCR and western blotting. c Overexpression efficiency of FTO and FTO-mut in TPC1 cells as determined by qRT-PCR and western blotting. d Total m6A modification levels after FTO knockdown or overexpression in PTC cells as determined by m6A RNA Methylation Quantification Kit. e-f CCK-8 assay (e) and colony formation assay (f) showing proliferation ability in K1 cells after FTO knockdown. g-h CCK-8 assay (g) and colony formation assay (h) showing proliferation ability after FTO overexpression in TPC1 cells. i Representative image of subcutaneous tumors excised from nude mice model administered with K1 cells infected with sh-NC and sh-FTO (n = 5). j-k Tumor volumes (j) and tumor weights (k) were determined after excision from nude mice in the above-mentioned groups. l Representative image of subcutaneous tumors excised from nude mice model administered with TPC1 cells infected with empty vector, FTO and FTO-mut. m-n Tumor volumes (m) and tumor weights (n) were determined after excision from nude mice model in the above-mentioned groups. *P < 0.05, **P < 0.01
Fig. 2 FTO inhibits PTC cell proliferation in vitro and in vivo. a Relative protein expression of FTO in the normal thyroid follicular epithelial cells and PTC cells as determined by western blotting. b Knockdown efficiency of si-FTO-1/2 in K1 cells as determined by qRT-PCR and western blotting. c Overexpression efficiency of FTO and FTO-mut in TPC1 cells as determined by qRT-PCR and western blotting. d Total m6A modification levels after FTO knockdown or overexpression in PTC cells as determined by m6A RNA Methylation Quantification Kit. e-f CCK-8 assay (e) and colony formation assay (f) showing proliferation ability in K1 cells after FTO knockdown. g-h CCK-8 assay (g) and colony formation assay (h) showing proliferation ability after FTO overexpression in TPC1 cells. i Representative image of subcutaneous tumors excised from nude mice model administered with K1 cells infected with sh-NC and sh-FTO (n = 5). j-k Tumor volumes (j) and tumor weights (k) were determined after excision from nude mice in the above-mentioned groups. l Representative image of subcutaneous tumors excised from nude mice model administered with TPC1 cells infected with empty vector, FTO and FTO-mut. m-n Tumor volumes (m) and tumor weights (n) were determined after excision from nude mice model in the above-mentioned groups. *P < 0.05, **P < 0.01CC BY · PubMed Central
Fig. 3 FTO inhibition of PTC growth by modulating glycolytic metabolism in vitro and in vivo. a Extra cellular acidification rate (ECAR) as determined by Seahorse metabolic analysis after transfection with si-NC and si-FTO in K1 cells. b-c Glucose uptake (b) and Lactate production (c) were determined after transfected with si-NC and si-FTO in K1 cells. d mRNA expression level of glycolytic enzymes was determined by qRT-PCR after FTO knockdown. e Protein expression level of GLUT1, HK-II and LDHA were determined by western blotting after FTO knockdown in K1 cells. f-g CCK-8 assay (f) and colony formation assay (g) showing proliferation ability after transfection with si-NC or si-FTO and simultaneous treatment with or without 2-Deoxyglucose (2-DG) in K1 cells. h Representative images of 18F-FDG uptake by micro-PET imaging in sh-NC and sh-FTO xenograft mouse models. Tumor glucose uptake is marked by red circles and maximum uptake values (SUVmax) for xenografts determined by FDG-PET are shown. i ECAR as determined by Seahorse metabolic analysis after FTO overexpression in TPC1 cells. j-k Glucose uptake (j) and Lactate production (k) were determined after FTO overexpression in TPC1 cells. l GLUT1, HK-II and LDHA protein expression levels as determined by western blotting after FTO overexpression in TPC1 cells. m Representative images of 18F-FDG uptake by micro-PET imaging in FTO overexpression xenograft mouse models. Tumor glucose uptake is indicated by red circles and maximum uptake values (SUVmax) for xenografts determined by FDG-PET are shown. *P < 0.05, **P < 0.01
Fig. 3 FTO inhibition of PTC growth by modulating glycolytic metabolism in vitro and in vivo. a Extra cellular acidification rate (ECAR) as determined by Seahorse metabolic analysis after transfection with si-NC and si-FTO in K1 cells. b-c Glucose uptake (b) and Lactate production (c) were determined after transfected with si-NC and si-FTO in K1 cells. d mRNA expression level of glycolytic enzymes was determined by qRT-PCR after FTO knockdown. e Protein expression level of GLUT1, HK-II and LDHA were determined by western blotting after FTO knockdown in K1 cells. f-g CCK-8 assay (f) and colony formation assay (g) showing proliferation ability after transfection with si-NC or si-FTO and simultaneous treatment with or without 2-Deoxyglucose (2-DG) in K1 cells. h Representative images of 18F-FDG uptake by micro-PET imaging in sh-NC and sh-FTO xenograft mouse models. Tumor glucose uptake is marked by red circles and maximum uptake values (SUVmax) for xenografts determined by FDG-PET are shown. i ECAR as determined by Seahorse metabolic analysis after FTO overexpression in TPC1 cells. j-k Glucose uptake (j) and Lactate production (k) were determined after FTO overexpression in TPC1 cells. l GLUT1, HK-II and LDHA protein expression levels as determined by western blotting after FTO overexpression in TPC1 cells. m Representative images of 18F-FDG uptake by micro-PET imaging in FTO overexpression xenograft mouse models. Tumor glucose uptake is indicated by red circles and maximum uptake values (SUVmax) for xenografts determined by FDG-PET are shown. *P < 0.05, **P < 0.01CC BY · PubMed Central
Fig. 4 APOE mRNA is regulated by FTO-mediated m6A modification through the m6A reader IGF2BP2. a Differentially expressed genes between si-NC group and si-FTO group in K1 cells as determined by RNA-sequencing. b Peak profiles in m6A modification after FTO knockdown in K1 cells as shown by MeRIP-sequencing. c Distribution of m6A peaks in mRNA transcripts of K1 cells. d The m6A consensus motif present in K1 cells. e Differentially expressed genes accompanied with elevated m6A peaks after FTO knockdown were filtered and APOE was identified as the direct target of FTO. f m6A modification of APOE mRNA was visualized by Integrative Genomics Viewer (IGV) software after FTO knockdown. The significantly increased m6A peak is indicated by red rectangles. g-j APOE mRNA and protein expression level as determined by qRT-PCR and western blotting after FTO knockdown or overexpression in PTC cells. k Relative APOE mRNA expression as determined by qRT-PCR after transfection with si-NC or si-FTO and simultaneous treatment with or without 3-deazaadenosine (DAA, a global methylation inhibitor) in K1 cells. l Direct binding between m6A antibody and APOE mRNA was validated by agarose electrophoresis and MeRIP assays in K1 cells. m Relative enrichment of m6A antibody and APOE mRNA as determined by MeRIP-qPCR after FTO knockdown in K1 cells. n-o Relative luciferase activity of APOE-Wt and APOE-Mut as determined after FTO knockdown or overexpression in PTC cells. p Half-life (t1/2) of APOE mRNA as determined by qRT-PCR after FTO knockdown in K1 cells. q Relative expression of APOE mRNA as determined by qRT-PCR after IGF2BP1–3 knockdown in K1 cells. r Half-life (t1/2) of APOE mRNA as determined by qRT-PCR after IGF2BP2 knockdown in K1 cells. s Direct binding between IGF2BP2 protein and APOE mRNA as validated by agarose electrophoresis and RIP assays in K1 cells. t Relative enrichment of IGF2BP2 protein and APOE mRNA as determined by RIP-qPCR after FTO knockdown in K1 cells. *P < 0.05, **P < 0.01
Fig. 4 APOE mRNA is regulated by FTO-mediated m6A modification through the m6A reader IGF2BP2. a Differentially expressed genes between si-NC group and si-FTO group in K1 cells as determined by RNA-sequencing. b Peak profiles in m6A modification after FTO knockdown in K1 cells as shown by MeRIP-sequencing. c Distribution of m6A peaks in mRNA transcripts of K1 cells. d The m6A consensus motif present in K1 cells. e Differentially expressed genes accompanied with elevated m6A peaks after FTO knockdown were filtered and APOE was identified as the direct target of FTO. f m6A modification of APOE mRNA was visualized by Integrative Genomics Viewer (IGV) software after FTO knockdown. The significantly increased m6A peak is indicated by red rectangles. g-j APOE mRNA and protein expression level as determined by qRT-PCR and western blotting after FTO knockdown or overexpression in PTC cells. k Relative APOE mRNA expression as determined by qRT-PCR after transfection with si-NC or si-FTO and simultaneous treatment with or without 3-deazaadenosine (DAA, a global methylation inhibitor) in K1 cells. l Direct binding between m6A antibody and APOE mRNA was validated by agarose electrophoresis and MeRIP assays in K1 cells. m Relative enrichment of m6A antibody and APOE mRNA as determined by MeRIP-qPCR after FTO knockdown in K1 cells. n-o Relative luciferase activity of APOE-Wt and APOE-Mut as determined after FTO knockdown or overexpression in PTC cells. p Half-life (t1/2) of APOE mRNA as determined by qRT-PCR after FTO knockdown in K1 cells. q Relative expression of APOE mRNA as determined by qRT-PCR after IGF2BP1–3 knockdown in K1 cells. r Half-life (t1/2) of APOE mRNA as determined by qRT-PCR after IGF2BP2 knockdown in K1 cells. s Direct binding between IGF2BP2 protein and APOE mRNA as validated by agarose electrophoresis and RIP assays in K1 cells. t Relative enrichment of IGF2BP2 protein and APOE mRNA as determined by RIP-qPCR after FTO knockdown in K1 cells. *P < 0.05, **P < 0.01CC BY · PubMed Central
Fig. 5 APOE is negatively correlated with FTO and regulates PTC proliferation by modulating glycolysis. a Relative expression levels of APOE as determined by qRT-PCR in 100 pairs of PTC tissues and adjacent non-cancerous tissues. b FTO is negatively correlated with APOE expression as shown in 100 pairs of PTC tissues. c FTO and APOE expressions showed a significantly negative correlation in TCGA database (Obtained from starBase). d Representative photographs of IHC staining showing APOE protein expression in PTC tissues and adjacent non-cancerous tissues (Cohort 2). Scale bars: 50 μm (400X). e-f CCK-8 assay (e) and colony formation assay (f) showing proliferation ability after transfection with si-FTO or co-transfected si-FTO and si-APOE in K1 cells. g ECAR as determined by Seahorse metabolic analysis after transfection with si-FTO or co-transfection with si-FTO and si-APOE in K1 cells. h-i Glucose uptake (h) and Lactate production (i) as determined after transfection with si-FTO or co-transfection with si-FTO and si-APOE in K1 cells. j Protein expression of GLUT1, HK-II and LDHA as determined by western blotting after APOE knockdown in K1 cells. k CCK-8 assay showing proliferation ability after transfection with empty vector or APOE and simultaneous treatment with or without 2-Deoxyglucose (2-DG) in K1 cells. l Representative image of subcutaneous tumors excised from nude mice model bearing K1 cells transfected with sh-NC, sh-FTO and sh-FTO+ sh-APOE (n = 5). m-n Tumor volumes (m) and tumor weights (n) determined after excision from nude mice in the above-mentioned groups. o Representative images of 18F-FDG uptake by micro-PET imaging in sh-NC, sh-FTO and sh-FTO+ sh-APOE xenograft mouse models. Tumor glucose uptake is indicated using red circles and maximum uptake values (SUVmax) for xenografts determined by FDG-PET are shown. *P < 0.05, **P < 0.01
Fig. 5 APOE is negatively correlated with FTO and regulates PTC proliferation by modulating glycolysis. a Relative expression levels of APOE as determined by qRT-PCR in 100 pairs of PTC tissues and adjacent non-cancerous tissues. b FTO is negatively correlated with APOE expression as shown in 100 pairs of PTC tissues. c FTO and APOE expressions showed a significantly negative correlation in TCGA database (Obtained from starBase). d Representative photographs of IHC staining showing APOE protein expression in PTC tissues and adjacent non-cancerous tissues (Cohort 2). Scale bars: 50 μm (400X). e-f CCK-8 assay (e) and colony formation assay (f) showing proliferation ability after transfection with si-FTO or co-transfected si-FTO and si-APOE in K1 cells. g ECAR as determined by Seahorse metabolic analysis after transfection with si-FTO or co-transfection with si-FTO and si-APOE in K1 cells. h-i Glucose uptake (h) and Lactate production (i) as determined after transfection with si-FTO or co-transfection with si-FTO and si-APOE in K1 cells. j Protein expression of GLUT1, HK-II and LDHA as determined by western blotting after APOE knockdown in K1 cells. k CCK-8 assay showing proliferation ability after transfection with empty vector or APOE and simultaneous treatment with or without 2-Deoxyglucose (2-DG) in K1 cells. l Representative image of subcutaneous tumors excised from nude mice model bearing K1 cells transfected with sh-NC, sh-FTO and sh-FTO+ sh-APOE (n = 5). m-n Tumor volumes (m) and tumor weights (n) determined after excision from nude mice in the above-mentioned groups. o Representative images of 18F-FDG uptake by micro-PET imaging in sh-NC, sh-FTO and sh-FTO+ sh-APOE xenograft mouse models. Tumor glucose uptake is indicated using red circles and maximum uptake values (SUVmax) for xenografts determined by FDG-PET are shown. *P < 0.05, **P < 0.01CC BY · PubMed Central
Fig. 6 FTO and APOE regulate glycolysis of PTC by modulating IL-6/JAK2/STAT3 signaling pathway. a Differentially expressed gene profiles based on GSEA of si-FTO and si-NC RNA-seq data. b Differential gene profiles based on GSEA of APOE gene expression profile data of TCGA. c Expression levels of IL-6/JAK2/STAT3 signaling pathway related proteins as determined by western blotting after FTO knockdown in K1 cells. d Expression levels of IL-6/JAK2/STAT3 signaling pathway related proteins as determined by western blotting after FTO overexpression in TPC1 cells. e Expression levels of IL-6/JAK2/STAT3 signaling pathway related proteins as determined by western blotting after APOE knockdown in K1 cells. f Expression levels of IL-6/JAK2/STAT3 signaling pathway related proteins as determined by western blotting after APOE overexpression in TPC1 cells. g Expression levels of GLUT1 protein and IL-6/JAK2/STAT3 signaling pathway related proteins as determined by western blotting after co-transfection of si-FTO and si-APOE in K1 cells. h. Mechanism diagram of the relationship of FTO, m6A modification, PTC tumor growth and glycolysis metabolism. *P < 0.05, **P < 0.01
Fig. 6 FTO and APOE regulate glycolysis of PTC by modulating IL-6/JAK2/STAT3 signaling pathway. a Differentially expressed gene profiles based on GSEA of si-FTO and si-NC RNA-seq data. b Differential gene profiles based on GSEA of APOE gene expression profile data of TCGA. c Expression levels of IL-6/JAK2/STAT3 signaling pathway related proteins as determined by western blotting after FTO knockdown in K1 cells. d Expression levels of IL-6/JAK2/STAT3 signaling pathway related proteins as determined by western blotting after FTO overexpression in TPC1 cells. e Expression levels of IL-6/JAK2/STAT3 signaling pathway related proteins as determined by western blotting after APOE knockdown in K1 cells. f Expression levels of IL-6/JAK2/STAT3 signaling pathway related proteins as determined by western blotting after APOE overexpression in TPC1 cells. g Expression levels of GLUT1 protein and IL-6/JAK2/STAT3 signaling pathway related proteins as determined by western blotting after co-transfection of si-FTO and si-APOE in K1 cells. h. Mechanism diagram of the relationship of FTO, m6A modification, PTC tumor growth and glycolysis metabolism. *P < 0.05, **P < 0.01CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 49 references

Cited by

See all 213

Metadata

Authors
Huang, J., Sun, W., Wang, Z., Lv, C., Zhang, T., Zhang, D., Dong, W., Shao, L., He, L., Ji, X., Zhang, P., & Zhang, H.
Affiliations
First Hospital of China Medical University (CN)
Corresponding author
Zhang, Hao
Venue
Journal of Experimental & Clinical Cancer Research
Published
2022-01-28
Volume
41
Issue
1
Pages
42-42
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W4210813406
Cited by
198
References
49
Citations by year
2026: 26 · 2025: 56 · 2024: 58 · 2023: 43 · 2022: 14
FWCI
14.53
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (81902726)
  • China Postdoctoral Science Foundation (2018M641739)
  • Natural Science Foundation of Education Bureau of Liaoning Province (QNZR2020009)
  • Natural Science Foundation of Liaoning Province (2020-MS-186)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
Keywords
FTO, N6-methyladenosine, m6A RNA methylation, papillary thyroid carcinoma, apolipoprotein E, mRNA stability, IGF2BP2, glycolysis, tumor growth, IL-6/JAK2/STAT3 signaling, tumor suppressor, glucose metabolism
MeSH terms
Alpha-Ketoglutarate-Dependent Dioxygenase FTO, Thyroid Cancer, Papillary, Adenosine, Apolipoproteins E, Glycolysis, Humans, Prognosis, RNA, Messenger, Cell Line, Tumor, Cell Proliferation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner. https://app.cochat.ai/papers/10.1186/s13046-022-02254-z
The paper
Huang, J., Sun, W., Wang, Z., Lv, C., Zhang, T., Zhang, D., Dong, W., Shao, L., He, L., Ji, X., Zhang, P., & Zhang, H. (2022). FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-022-02254-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.